New drug duo shows promise for Hard-to-Treat gynecological cancers

NCT ID NCT05512208

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times

Summary

This study tests two drugs, VS-6766 and defactinib, in people with certain gynecological cancers that have come back. The goal is to see if the combination can shrink tumors and how safe it is. About 55 adults with specific gene mutations (RAS, BRAF, or NF1) will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AdventHealth

    RECRUITING

    Orlando, Florida, 32804, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Louisiana State University Medical Center New Orleans

    RECRUITING

    New Orleans, Louisiana, 70112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73117, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of New Mexico Comprehensive Cancer Center

    RECRUITING

    Albuquerque, New Mexico, 87131, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.